Heart attack death rates rose by 1.2% among adults younger than age 55 who were hospitalized between 2011 and 2022 with a first severe heart attack, according to a February study published in the ...
The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...
The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...
Health and Me on MSN
When every second counts: Mastering cardiovascular emergencies
Timely recognition of symptoms like chest pain, breathlessness, syncope, palpitations, or sudden neurological deficits can ...
A bivalent messenger RNA vaccine targeting both the ancestral and omicron BA.4–BA.5 sublineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Pfizer–BioNTech) was introduced in ...
Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...
Cardiologist evaluation for post-noncardiac surgery PMI patients reduces one-year risks of major adverse cardiac events and all-cause death.
Myocardial infarction is an ischemic disease in which a coronary artery supplying blood to the heart muscle is stenotic or obstructed, resulting in cardiac tissue necrosis. Due to the irreversible ...
The risk for major adverse cardiovascular events is a recognized, important complication reported among patients with ANCA-associated vasculitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results